Urinary stone disease: assessment and management

Background: Urinary stones affect one in 10 Australians. The majority of stones pass spontaneously, but some conditions, particularly ongoing pain, renal impairment and infection, mandate intervention. Objective: This article explores the role of the general practitioner in the assessment and management of urinary stones. Discussion: The assessment of acute stone disease should determine the location, number and size of the stone(s), which influence its likelihood of spontaneous passage. Conservative management, with the addition of alpha blockers to facilitate passage of lower ureteric stones, should be attempted in cases of uncomplicated renal colic. Septic patients require urgent drainage and antibiotics. Other indications for referral and intervention include ongoing pain, renal impairment and stone size unlikely to pass spontaneously. There are many ways to eliminate stones, but laser lithotripsy is being used with increasing frequency. Up to 50% of people with a first presentation of stone disease will have a recurrence within 5 years. General advice for stone prevention consists of increasing fluid intake, especially water (sufficient to maintain dilute urine output), avoiding added salt and maintaining a well balanced low oxalate diet. Some patients may require a more detailed metabolic assessment and specific dietary advice

Comparison of cost of care for tethered versus non-tethered ureteric stents in the management of uncomplicated upper urinary tract stones

Background: Many surgeons use a stent after ureteroscopic lithotripsy (URSL). For short-term stenting purposes, a surgeon has the choice of either a tethered or a non-tethered stent. Stents may be associated with complications that entail an additional cost to their use. There is a paucity of data on the direct healthcare cost of using stent type after either primary or secondary URSL. Methods: We retrospectively reviewed medical records for patients who underwent URSL for uncomplicated urolithiasis between January 2013 and December 2013 at two tertiary referral hospitals. Costs data was sourced from the costing department with complete data available for 134 patients. The overall medical care cost was estimated by computing the cost of surgery, stent-related emergency department presentations, re-admissions and stent removal. Results: A total of 113 patients had tethered stents and 21 had non-tethered stents, with similar age and gender composition between the two groups and complications rates. The mean cost of URSL and stent placement was A$3071.7 ± A$906.8 versus A$3423.8 ± A$808.4 (P=0.049), mean cost of managing complications was A$309.4 ± A$1744.8 versus A$31.3 ± A$98.9 (P=0.096), mean cost of out-patient clinic stent removal was A$222.5 ± A$60 versus A$1013.6 ± A$75.4 (P<0.001) for endoscopic stent removal, overall mean cost of care was A$3603.6 ± A$1896.7 versus A$4468.1 ± A$820.8 (P=0.042) for tethered and non-tethered stents, respectively. Conclusion: It is cheaper to use a tethered ureteric stent compared with non-tethered stents for short-term stenting after uncomplicated URSL, with a mean cost saving of A$864.5

The Influence of Body Mass Index on Outcomes in Ureteroscopy: Results from the Clinical Research Office of Endourological Society URS Global Study

Introduction: Although ureteroscopy (URS) has been established as a viable treatment for stones in obese patients, its safety and success has not been fully elucidated. The current study describes the worldwide prevalence of obesity in patients with urolithiasis and examines trends in URS outcomes, safety, and efficacy